Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016

Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016
Published Jun 22, 2016
138 pages — Published Jun 22, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016, provides in depth analysis on Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2)
- The report reviews Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of admi

  
Source:
Document ID
GMDHC0101TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents27
  List of Tables71
  List of Figures81
Introduction91
  Global Markets Direct Report Coverage91
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Overview101
Therapeutics Development114
  Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Stage of Development111
  Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Therapy Area121
  Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Indication132
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Pipeline Products Glance152
  Late Stage Products151
  Early Stage Products161
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Companies177
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Products under Development by Universities/Institutes242
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Therapeutics Assessment265
  Assessment by Monotherapy/Combination Products261
  Assessment by Mechanism of Action271
  Assessment by Route of Administration281
  Assessment by Molecule Type292
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Companies Involved in Therapeutics Development3119
  AbbVie Inc.312
  Advinus Therapeutics Ltd331
  ArQule, Inc.341
  BeiGene, Ltd.351
  Bristol-Myers Squibb Company361
  Celgene Corporation371
  CrystalGenomics, Inc.381
  Genentech, Inc.391
  Hanmi Pharmaceuticals, Co. Ltd.401
  LSK BioPartners, Inc.411
  Merck KGaA421
  Ono Pharmaceutical Co., Ltd.431
  Pharmacyclics, Inc.441
  Principia Biopharma Inc.451
  Redx Pharma Plc461
  Simcere Pharmaceutical Group471
  Sunesis Pharmaceuticals, Inc.481
  Takeda Pharmaceutical Company Limited491
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Drug Profiles5067
  acalabrutinib Drug Profile504
  Antisense Oligonucleotides to Activate BTK for X-linked Agammaglobulinemia Drug Profile541
  ARQ-531 Drug Profile551
  BGB-3111 Drug Profile562
  CG-026806 Drug Profile581
  CG-036806 Drug Profile591
  Drug to Inhibit BTK for Undisclosed Indications Drug Profile601
  EBI-1266 Drug Profile611
  EBI-1367 Drug Profile621
  HCI-1401 Drug Profile631
  HCI-1684 Drug Profile641
  HM-71224 Drug Profile651
  ibrutinib Drug Profile6625
  M-2951 Drug Profile911
  M-7583 Drug Profile921
  ONO-4059 Drug Profile932
  PLS-123 Drug Profile951
  PNQ-154 Drug Profile961
  PNQ-849 Drug Profile971
  PRN-1008 Drug Profile982
  PRN-473 Drug Profile1001
  RDX-002 Drug Profile1011
  RG-7845 Drug Profile1021
  Small Molecule to Inhibit Bruton's Tyrosine Kinase for Arthritis Drug Profile1031
  Small Molecule to Inhibit Bruton Tyrosine Kinase for Inflammation Drug Profile1041
  Small Molecule to Inhibit BTK for Immunology Drug Profile1051
  Small Molecule to Inhibit BTK for Inflammation, Autoimmune Disorders and Cancer Drug Profile1061
  Small Molecule to Inhibit BTK for Oncology Drug Profile1071
  Small Molecules to Inhibit BTK for Oncology Drug Profile1081
  Small Molecules to Inhibit BTK for Rheumatoid Arthritis Drug Profile1092
  SNS-062 Drug Profile1112
  spebrutinib besylate Drug Profile1132
  TAK-020 Drug Profile1151
  X-022 Drug Profile1161
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Dormant Projects1173
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Discontinued Products1201
Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) Featured News &Press Releases12116
  Jun 06, 2016: AbbVie Builds Upon Robust Body of IMBRUVICA (ibrutinib) Data with Phase 3 Longer-Term Studies in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Presented at the American Society of Clinical Oncology Annual Meeting1212
  Jun 01, 2016: NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund1231
  May 31, 2016: Janssen's IMBRUVICA (ibrutinib) Approved by European Commission for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia1241
  May 24, 2016: REDX PHARMA: Proof of concept with key oncology lead1251
  May 18, 2016: AbbVie To Present Data on IMBRUVICA (ibrutinib) at ASCO 20161251
  May 18, 2016: Janssen to Present Data on Ibrutinib at the 2016 American Society of Clinical Oncology Annual Meeting1261
  May 12, 2016: Health Canada Approves IMBRUVICA (ibrutinib) for the Treatment of Waldenstroms Macroglobulinemia1271
  May 09, 2016: U.S. FDA Expands IMBRUVICA (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia and New Indication for Small Lymphocytic Lymphoma Patients1282
  Apr 29, 2016: European Medicines Agency Issues Positive Opinion for the Use of IMBRUVICA (ibrutinib) as a First-Line Treatment for Chronic Lymphocytic Leukemia Patients1301
  Apr 29, 2016: Janssen's IMBRUVICA (ibrutinib) Receives Positive CHMP Opinion for Expanded Use in Previously Untreated Chronic Lymphocytic Leukaemia Patients1311
  Mar 23, 2016: Sunesis Pharmaceuticals Announces First Subject Dosed in Phase 1A Healthy Volunteer Study Evaluating Oral Non-Covalent BTK-inhibitor SNS-0621321
  Mar 14, 2016: Diplomat Now Dispensing IMBRUVICA as First-Line Therapy for Chronic Lymphocytic Leukemia1321
  Mar 07, 2016: BeiGene Receives Approval to Initiate Clinical Trials in China With BGB-31111331
  Mar 04, 2016: U.S. FDA Approves IMBRUVICA (ibrutinib) for First-line Treatment of Chronic Lymphocytic Leukemia1332
  Feb 25, 2016: Acalabrutinib recommended for orphan drug designation in Europe for three indications1352
Appendix1372
  Methodology1371
  Coverage1371
  Secondary Research1371
  Primary Research1371
  Expert Panel Validation1371
  Contact Us1371
  Disclaimer1381

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-BTK-Bruton-Agammaglobulinemia-Tyrosine-Kinase-or-B-Cell-Progenitor-Kinase-or-Agammaglobulinemia-Tyrosine-Kinase-or-EC-2-7-10-2-Pipeline-Review-H1-2016-2088-15998>
  
APA:
Global Markets Direct - Market Research. (2016). Tyrosine-Protein Kinase BTK (Bruton Agammaglobulinemia Tyrosine Kinase or B-Cell Progenitor Kinase or Agammaglobulinemia Tyrosine Kinase or EC 2.7.10.2) - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Tyrosine-Protein-Kinase-BTK-Bruton-Agammaglobulinemia-Tyrosine-Kinase-or-B-Cell-Progenitor-Kinase-or-Agammaglobulinemia-Tyrosine-Kinase-or-EC-2-7-10-2-Pipeline-Review-H1-2016-2088-15998>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.